JAMA Internal Medicine
AUGUST 11, 2024
This cohort study evaluated the associations of plant and animal fat intake with cardiovascular disease and overall mortality outcomes.
pharmaphorum
AUGUST 11, 2024
The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic medicines category.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
AUGUST 11, 2024
This cohort study of patients with type 2 diabetes compares the rates of hyperkalemia and renin-angiotensin system (RAS) inhibitor persistence in those who used glucagon-like peptide 1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase 4 inhibitors (DPP-4is).
FDA Law Blog
AUGUST 11, 2024
By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued two new Untitled Letters this summer after 5 months without any letter activity. The letters are vastly different from one another in subject matter, but together they make a cruel summer of OPDP enforcement against industry. [Editorial note – the Gen X’er included that link first – for the arguably more popular reference, read on.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Drug Patent Watch
AUGUST 11, 2024
This chart shows the pharmaceutical companies with the most patents in Malaysia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.
Drug Patent Watch
AUGUST 11, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
Drug Patent Watch
AUGUST 11, 2024
The development of generic drugs is a crucial aspect of the pharmaceutical industry, as it provides affordable alternatives to expensive […] Source
Expert insights. Personalized for you.
95 
Let's personalize your content